Kelley Wright
Investment Q Trends
Chuck Carlson
The DRIP Investor
Paul Goodwin
Cabot China & Emerging Markets Report
John Reese
Validea

Top stocks 2013: InVivo and PetroBakken


Bookmark and Share
by Tom Bishop, editor BI Research

Tom BishopInVivo (NVIV) was my top speculative pick for 2012 and it remains my favorite idea for appreciation in 2013. Although the story has taken longer to play out than originally expected, I will definitely stick with it for potential outsized gain in 2013.

My income favorite again in 2013 is PetroBakken (PBKEF), which, to cut right to the chase, pays a $0.96 annual dividend. This works out to 8.7%.

InVivo has developed a biodegradable, bio-polymer scaffolding device. When implanted into a spinal cord injury (SCI), this device reduces swelling and inflammation that would otherwise cause total paralysis below the point of injury.

The company seemed poised to gain FDA clearance to take its device into clinical trials earlier this year. However, InVivo’s plans to move into new manufacturing space late in 2012 prompted the FDA to delay clearance.


The FDA delayed the trial until InVivo moved into this new facility, completed validation of it and produced compliant batches there. Although this delayed the time line a good 6-9 months, these steps are now done,

The company has tested its device in over 40 monkeys with SCI and every one has walked again within 2-3 weeks. Trial results in monkeys are as good a proxy for what will happen in humans as there is. So this is a very exciting time. Human trials should start in the first part of 2013.

While there are no guarantees, the success on all 40 monkeys tested and the involvement of Noble Prize candidate Bob Langer of MIT, gives us a measure of confidence.

Meanwhile, PetroBakken is an energy exploration and development (90% oil) company; its roots are in the Canadian portion of the Bakken/Williston Basin.

That portion of the company has turned into a cash cow that helps fund growth in new fields like the Cardium in Alberta (and other newer opportunities) where it can use its skills in horizontal drilling and well stimulation.

Despite annual decline rates in the 35% range and the sale of 4,000 barrels of non-core production to refinance and reposition itself for growth, the company is on track to increase production by 10% in 2012 to an exit rate of 52-56,000 boepd, with more of the same likely in 2013.

Accordingly, barring a collapse in oil prices, the 8.7% dividend appears reasonably secure.

Learn more about this financial newsletter at Tom Bishop's BI Research.

Related articles

Advertisement
Banner
News Flash

US Natural Gas ETF: On a roll
by Doug Fabian, editor Successful Investing

One area I think is ready for a new buy is natural gas. After experiencing a sharp decline from November through early January, natural gas prices have been on a roll.


Read more...

 

Split buys? HOMB and Noble Energy
by Neil Macneale, editor 2-for-1 Stock Split Newsletter

Each month, we add one stock to our model portfolio based upon those companies that have announced 2-for-1 stock splits; after a meager number of splits over the past year, we have a nice collection of six splits elect from this month.


Read more...


   

WisdomTree targets global bonds
by Mark Salzinger, editor The Investor's ETF Report

While most investors diversify the equity portions of their portfolio with allocations to foreign stocks, few diversify their bond holdings internationally. WisdomTree recently introduced the first ETF to invest in a truly global portfolio of corporate bonds.


Read more...

 

Express Scripts: Obamacare buy
by J. Royden Ward, editor Cabot Benjamin Graham Value Investor

I am attracted to healthcare stocks because the confusion surrounding “ObamaCare” has held healthcare stock prices back. I think Express Scripts (ESRX) is very likely to shine in 2013.


Read more...

 

Hodges: High conviction funds
by Walter Frank, editor MoneyLetter

Over the last two months, Hodges Fund (HDPMX) has made a strong run to the top echelons of our domestic stock fund rankings. And one of its siblings, Hodges Small Cap (HDPSX) has been within the top decline of the small blend category from 2009 through last year, and is in the top 20% this year.


Read more...

 

United Natural: A play on Whole Foods
by Mark Skousen, editor Hedge Fund Trader Alert

We’ve recommended Whole Foods Market (WFM) from time to time, and the stock has moved up sharply in the past three years, but I’d like to suggest an alternative -- one of Whole Foods’ primary suppliers, United Natural Foods (UNFI).


Read more...

 

Timing expert eyes India
by Sy Harding, editor Street Smart Report

The money flow and momentum reversals in India's Bombay Index have now been enough to trigger buy signals on intermediate-term indicators. With this new buy signal, we have added a position in the iShares India 50 ETF (INDY) to our portfolio.


Read more...

 

Value investor goes with Guess
by Charles Mizrahi, editor Hidden Values Alert

Guess?, Inc. (GES) is a holding in our special situation portfolio; its strong product quality has created brand name recognition and a loyal consumer following.


Read more...

 

MGAM: Bingo, lotteries, casinos
by Jim Oberweis, Jr., editor The Oberweis Report

Multimedia Games Holding Company (MGAM) makes innovative gaming systems for Native American and commercial casino operators in North America, lottery operators, and charity and commercial bingo operators.


Read more...

 

Fidelity expert: Bowers' bond bets
by Jack Bowers, editor Fidelity Monitor & Insight

If you’ve been worried that the bond market might take a big hit, you can relax. Indeed, while bond funds may lag stock funds over the next 5-10 years, they still have a decent shot at keeping up with inflation, and they remain an excellent way to cut risk in a blended portfolio.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary